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Our group recently identified InsB, an ESAT-6-like antigen belonging to the Mtb9.9
subfamily within the Esx family, in the Mycobacterium tuberculosis Korean Beijing
strain (Mtb K) via a comparative genomic analysis with that of the reference Mtb
H37Rv and characterized its immunogenicity and its induced immune response in
patients with tuberculosis (TB). However, the vaccine potential of InsB has not been
fully elucidated. In the present study, InsB was evaluated as a subunit vaccine in
comparison with the most well-known ESAT-6 against the hypervirulent Mtb K. Mice
immunized with InsB/MPL-DDA exhibited an antigen-specific IFN-γ response along
with antigen-specific effector/memory T cell expansion in the lungs and spleen upon
antigen restimulation. In addition, InsB immunization markedly induced multifunctional
Th1-type CD4+ T cells coexpressing TNF-α, IL-2, and IFN-γ in the lungs following Mtb
K challenge. Finally, we found that InsB immunization conferred long-term protection
against Mtb K comparable to that conferred by ESAT-6 immunization, as evidenced by
a similar level of CFU reduction in the lung and spleen and reduced lung inflammation.
These results suggest that InsB may be an excellent vaccine antigen component for
developing a multiantigenic Mtb subunit vaccine by generating Th1-biased memory T
cells with a multifunctional capacity and may confer durable protection against the highly
virulent Mtb K.
Keywords: Mycobacterium tuberculosis, Beijing genotype, ESAT-6, InsB, subunit vaccine
INTRODUCTION
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major public health
threat worldwide as the top infectious disease in terms of morbidity and mortality (WHO, 2017).
Despite the global use of Bacillus Calmette-Guerin (BCG) vaccination and available TB treatments,
TB reportedly showed an incidence of 10.4 million cases and caused 1.7 million deaths in 2016
(WHO, 2017). Although the prevention of TB is the most effective control measure for reducing the
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incidence of TB, the protective efficacy of BCG, which is the only
approved vaccine for TB (Nemes et al., 2018), is thought to be
insufficient to protect against pulmonary TB and latent infection,
and its highly variable results among different geographical
locations indicate that Mtb genotypes with different virulence
levels might be dominant in different regions (Pitt et al., 2013).
To develop new prophylactic vaccines capable of replacing
or improving the BCG vaccine, researchers have moved many
vaccine candidates into the clinical phase (Kaufmann et al., 2017).
The identification and discovery of novel antigens is the initial
and important step in new vaccine development (Singh et al.,
2014). Importantly, an understanding of antigenic variation and
the differential virulence levels of clinically prevalent Mtb strains
is one of the factors considered in TB vaccine development
(Ernst, 2017; Chae and Shin, 2018; Chiner-Oms et al., 2018).
In addition, studies of newly emerging strains displaying a
wide spectrum of virulence and fitness have been considered as
valuable for developing new vaccines, as screening vaccines with
laboratory-adapted strains have been regarded as one possible
limitation in the current field (Henao-Tamayo et al., 2015). In
particular, the Mtb Beijing genotype is highly dominant in East
Asian countries, and the rate of isolation of strains belonging to
the Mtb Beijing family has increased worldwide, which indicates
that the BCG vaccine might provide a relatively low level of
protection against these strains (Abebe and Bjune, 2006; Kremer
et al., 2009). Furthermore, epidemiological studies have suggested
that extensive and continuous BCG vaccination may be one
of the forces causing the emergence of the Beijing genotype
(Abebe and Bjune, 2006), indicating that the global control of
Mtb Beijing strains is important due to their association with
drug resistance and their ability to evade BCG-conferred vaccine
efficacy (Kremer et al., 2009). Furthermore, the failure of the
MVA85A vaccine trial may have occurred because it was tested
not against any clinical strains but only against laboratory-
adapted strains without considering the prevalent local strains in
the region of clinical trials even though MVA85A was extensively
tested in animal settings (Groschel et al., 2017). In this context,
greater attention to the varying fitness of Mtb strains throughout
the regions should be preferentially required for the development
of a vaccine and testing of its efficacy. Thus, the protective
efficacy of new TB vaccine candidates should be tested against the
prevailing local strains, such as Mtb Beijing strains, in addition to
the laboratory-adapted strains (van Soolingen et al., 1995).
In this regard, we previously characterized the genetic
features of the Mtb Korean Beijing strain (Mtb K) causing a
high school TB outbreak in South Korea via whole-genome
sequencing (Han et al., 2015) and a comparative genomics
approach to analyze the reference Mtb H37Rv strain (GenBank
accession no. NC_000962) and Mtb K (GenBank accession
no. CP007803.1). Interestingly, we identified MTBK_24790
(GenBank: AIB49023.1, hereafter referred to as InsB according
to our previous study) (Park et al., 2014), an ESAT-6-like family
protein encoded within the 5.7 kb gene cluster specifically
inserted into the genome of Mtb strain K. Further analysis
of sequences homologous to InsB by protein BLAST analysis1
1https://blast.ncbi.nlm.nih.gov
revealed that an identical protein in the reported Mtb genome
was found only in CDC1551, which was well characterized as
a highly transmissible and virulent strain during TB outbreaks
in the United States (Valway et al., 1998). In addition, our
previous studies demonstrated that the recombinant InsB of
Mtb K demonstrated a potential to improve the sensitivity of
immunodiagnosis in both humans and mice (Park et al., 2014;
Hur et al., 2016) by inducing an immune response differing from
that induced by ESAT-6.
The esx family consists of 23 members, and the corresponding
Esx proteins are involved in host-pathogen interactions
during Mtb infection (Skjot et al., 2002). In addition, these
secreted Esx family proteins are considered to be the most
immunodominant antigens recognized by the host immune
system and have therefore been exploited to develop vaccines and
immunodiagnostic tools for TB control (Groschel et al., 2016).
Among the Esx family proteins, the Mtb9.9 subfamily proteins,
with 94 amino acids and a molecular size of approximately
9.9 kDa, comprises five members: EsxN, EsxI, EsxL, EsxO, and
EsxV (Knudsen et al., 2014; Villarreal et al., 2014). Although
the function of Mtb9.9 subfamily antigens remains unknown,
Peng et al. (2012) reported that the Mtb9.9 subfamily proteins
are immunogenic in C57BL/6 mice by inducing humoral and
Th1-type cellular memory responses, suggesting that they may
serve as potent subunit vaccine candidates. Moreover, Villarreal
et al. (2014) demonstrated that the strongest CD4+ T-cell
immune responses were observed for EsxO antigen and EsxV,
which are located in region of difference (RD) 7 and RD9 and
are absent in BCG; EsxV was the most prominent antigen to
induce CD8+ T cell immunity among the Mtb9.9 subfamily
antigens. Furthermore, Mahmood et al. (2011) reported that
EsxV antigen induced a strong Th1 immune response; reduced
the bacterial burden in the lungs of Mtb-infected mice; caused
increased IFN-γ, IL-12 and IgG2a levels; and can thus serve
as a subunit vaccine candidate. Therefore, these immunogenic
antigens may be useful for designing and developing more
effective TB vaccines.
Interestingly, a homologous protein sequence analysis of InsB
revealed that InsB belongs to the Mtb9.9 protein subfamily by
showing >95% protein identity of InsB to all members of the
Mtb9.9 protein subfamily (EsxI, EsxL, EsxN, EsxO, and EsxV)
(Park et al., 2014), and Mtb K has one more copy of the region of
the InsB cluster with an unknown function. In addition, despite
their low mass, the Mtb9.9 protein antigens contain at least five
distinct T cell epitopes. Moreover, they are the specific proteins of
Mtb that are not detected in BCG (Peng et al., 2012). In addition,
biased Th1-type cellular and humoral memory responses to
the Mtb9.9 protein family have been shown in animal studies,
and multiple cytokines and multicytokine-producing T cells are
induced by these proteins. Thus, we should be able to evaluate
their contributions to the development of diagnostic tools and
vaccines for TB control if a new Esx antigen or its epitopes are
identified (Peng et al., 2012).
Our group has searched for optimal vaccine antigen
combinations aimed at developing a multiantigenic vaccine
and has attempted to characterize well-known or less well-
known antigens in vitro and in vivo (Kim et al., 2013;
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Choi et al., 2015, 2017; Kwon et al., 2017). Thus, the primary goal
of our current study was to investigate the vaccine potential of
InsB based on comparative genomic analysis selection as a single
antigen against Mtb K, which remains predominantly isolated
in South Korea (Kang et al., 2010). In the present study, the
immunogenicity and the potential protective efficacy of InsB and
ESAT-6 as subunit vaccines were compared in a head-to-head
manner using a Mtb Beijing strain challenge model.
MATERIALS AND METHODS
Animals and Ethics Statement
Specific pathogen-free female C57BL/6 mice (6–7 weeks of
age) were purchased from Jackson Laboratory (Bar Harbor,
ME, United States) and maintained under barrier conditions
in a BL-3 biohazard animal facility of the Laboratory Animal
Research Center at Yonsei University College of Medicine (Seoul,
South Korea). This study was carried out in accordance with the
recommendations of the Korean Food and Drug Administration
(KFDA), the Korean Institutional Animal Ethical Committee.
The animal experimental protocols used in this vaccine study
were approved by the Korean Institutional Animal Ethical
Committee (Permit Number: 2014-0197-3).
Cloning and Purification of Recombinant
InsB Protein
Recombinant ESAT-6 and InsB proteins were purified as
previously described (Park et al., 2014; Hur et al., 2016).
Briefly, Mtb K was grown in Sauton’s media at 37◦C,
and its genomic DNA was prepared by using N-acetyl-
N,N,N-trimethyl ammonium bromide (CTAB) buffer. PCR
was performed to amplify the InsB sequence with a primer
set (F: 5′-TTGCATATGACGATCAATT-ATCAGTTCGG-3′; R:
5′- GCGGATCCAGCCCAGCT-GGAACCCACT-3′). The PCR
product was confirmed and inserted into pET11a_KB with the
NdeI and BamH1 restriction enzymes. The vector DNA was
transferred to Escherichia coli DH5α, and plasmids were then
extracted using an Expin Plasmid Purification Kit (GeneAll,
Seoul, South Korea). This recombinant protein was transferred
again to E. coli BL21 (DE3) and purified with Ni-NTA resin
for histidine affinity chromatography using AKTA fast protein
liquid chromatography (FPLC) with a Mono Q anion exchange
column. Following separation by FPLC, proteins were confirmed
by SDS-PAGE.
Antigen Immunization and Mtb K
Challenge in Mice
For the adjuvant control, mice were immunized subcutaneously
3 times at 3-week intervals with dimethyldioctadecylammonium
(DDA) liposomes (50 µg) containing monophosphoryl lipid-A
(MPL, 5 µg). MPL and DDA were purchased from Sigma-Aldrich
(St. Louis, MO, United States). MPL was mixed in distilled water,
and this mixture was heated in a water bath at 65◦C for 30 s and
then sonicated for 30 s, and this heating and sonication steps were
repeated three times. MPL was subsequently mixed with DDA,
which was dissolved in distilled water, at a 2:1 (MPL:DDA) ratio
immediately before use. For ESAT-6 and InsB immunization,
mice were immunized subcutaneously 3 times at 3-week intervals
with a formulation containing each antigen (InsB, 5 µg; ESAT-
6, 5 µg) and MPL-DDA (this adjuvant concentration was
the same as that used for the adjuvant control groups). The
BCG-vaccinated groups (as a positive control for the efficacy
testing experiment for the TB vaccine) were subcutaneously
vaccinated with 2.0 × 105 CFU of BCG Pasteur 1173 P2 at
the time of the 2nd immunization using the antigens. Three
weeks after the last immunization, adjuvant controls, antigen-
immunized mice and BCG-vaccinated mice were aerogenically
infected with Mtb K as previously described (Kim et al., 2013).
Briefly, the mice were exposed to Mtb K for 60 min in the
inhalation chamber of an airborne infection apparatus calibrated
to deliver a predetermined dose (Glas-Col, Terre Haute, IN,
United States). To confirm the initial bacterial burden, four mice
were euthanized one day later, and an analysis of these mice
revealed that approximately 200 CFUs were delivered to the lungs
of each mouse.
Splenocyte and Lung Cell Preparation
Single-cell suspensions from lung and spleen were prepared
as follows. The spleen and lung from mice of each group
were homogenized. Spleen homogenates were filtered through a
40µm cell strainer (BD Bioscience, San Diego, CA, United States)
in RPMI medium supplemented with 2% fetal bovine serum
(FBS, Biowest, Nuaillé, France) using a sterile 10 mL syringe.
The lung cells were prepared as previously described (Kim
et al., 2015). Briefly, the lung homogenates were incubated in
3 mL of cellular dissociation buffer RPMI medium (Biowest)
containing 0.1% collagenase type IV (Worthington Biochemical
Corporation, NJ, United States) and 1 mM CaCl2 and 1 mM
MgCl2) for 15 min at 37◦C, and then lung cells were filtered
through a 40 µm cell strainer in RPMI medium supplemented
with 2% fetal bovine serum using a sterile 10 mL syringe.
The erythrocytes were lysed using red blood cell lysis buffer
(Sigma-Aldrich) for 5 min at room temperature, and then single-
cells were washed twice with RPMI medium supplemented
with 2% FBS.
Measurement of IFN-γ Production
Three weeks after the final immunization of antigens, single-
cell suspensions (1 × 106/mL) from the lung and spleen of
adjuvant-, BCG-, and antigen-immunized mice were stimulated
with purified proteins (InsB, 2 µg/mL; ESAT-6, 2 µg/mL) for
24 h at 37◦C. IFN-γ cytokine levels were analyzed in the culture
supernatant via sandwich enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s protocol. Additionally,
single-cell suspensions were stimulated with purified proteins
(InsB; 2 µg/mL, ESAT-6; 2 µg/mL) for 12 h at 37◦C
in the presence of GolgiStop (eBioscience, San Diego, CA,
United States), and then the cells were stained with Live/Dead
Stain (InvivoGen, San Diego, CA, United States) and with
anti-CD4 (PerCp-Cy5.5, eBioscience), anti-CD8 (APC-Cy7,
eBioscience), and anti-CD3 (BV421, eBioscience) antibodies
for 30 min at 4◦C. Next, the stained cells were fixed and
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permeabilized using a Cytofix/Cytoperm kit (BD Biosciences,
San Jose, CA, United States) according to the manufacturer’s
protocol and then stained with anti-IFN-γ (PE, eBioscience).
The cells were analyzed with a FACSVerse flow cytometer using
FlowJo software.
Analysis of Antigen-Specific
Multifunctional T Cells
Single-cell suspensions from the lung and spleen of Mtb
K-infected mice at 3 weeks after the final immunization and
at 4 and 9 weeks postchallenge were stimulated with purified
proteins (InsB; 2 µg/mL, ESAT-6; 2 µg/mL) for 12 h at 37◦C
in the presence of GolgiStop. The cells were stained using a
Live/Dead Fixable Aqua Dead Cell stain kit (BV510, Invitrogen)
and with anti-CD3 (FITC, eBioscience), anti-CD4 (PerCp-
Cy5.5), anti-CD8 (APC-Cy7), anti-CD44 antibodies (eFluor 450,
eBioscience) for 30 min at 4◦C and then fixed and permeabilized
using a Cytofix/Cytoperm kit according to the manufacturer’s
protocol. Next, the cells were stained with anti-IFN-γ (PE,
eBioscience), anti-TNF-α (APC, eBioscience) and anti-IL-2 (PE-
Cy7, eBioscience) for 30 min at 4◦C. Cells stained with the
appropriate isotype-matched immunoglobulins, which included
rat IgG2b kappa (eFluor 450, eBioscience), mouse IgG1 kappa
(PE, eBioscience), rat IgG1 kappa (APC, eBioscience), and rat
IgG2b kappa (PE-Cy7, eBioscience) as the isotype controls
for anti-CD44, IFN-γ, TNF-α, and IL-2 Abs, respectively,
were used for discriminating cytokine-producing cells. The
cells were analyzed with a FACSVerse flow cytometer using
FlowJo software. To reduce false positives of cytokine-producing
populations caused by non-specific staining, fewer than 10 cells
in lung and 15 cells in spleen were considered as zero.
Evaluation of Bacterial Burden and Lung
Inflammation
The numbers of viable bacteria in the lung and spleen of Mtb
K-infected mice were obtained for CFU counts. Briefly, each
bacterial count was determined by plating serial dilutions of
the organ homogenates onto Middlebrook 7H10 agar (Becton
Dickinson, Franklin Lakes, NJ, United States) supplemented
with 10% OADC enrichment medium until the late-exponential
phase. After 3 weeks of incubation at 37◦C, the numbers
of colonies were then counted, and the values are reported
as the mean log10 CFUs ± SDs per gram of lung and
spleen tissues. The lung samples collected for histopathology
were preserved overnight in 10% normal buffered formalin,
embedded with paraffin, cut into 4–5-mm sections, and stained
with hematoxylin-eosin (H&E). Then, the severity of lung
inflammation was examined using the ImageJ program (National
Institutes of Health, United States) as previously described (Jeon
et al., 2011; Kwon et al., 2017). In brief, three images of each lung
section (six mice/group) were obtained at 20× magnification
using a Nikon ECLIPSE Ci (Nikon Corporation, Japan). After
color deconvolution of each image into the red channel using
the ImageJ program, the inflamed and non-inflamed areas could
be observed as dark and light areas, respectively. Image analysis
was independently conducted at each indicated time point.
By discriminating inflamed areas from non-inflamed areas, the
relative mean percentages of inflammation in the lung images
from each group were obtained. The data are displayed using
box-and-whisker plots.
Statistical Analyses
Statistical analyses were conducted using GraphPad Prism
V5.0 (GraphPad Software, San Diego, CA, United States). The
differences between two groups were analyzed using unpaired
Student’s t-test. One-way ANOVA followed by Tukey’s multiple
comparison test was used to analyze differences between more
than two groups. All the values are expressed as the means
(±SDs). Differences with ∗p < 0.05, ∗∗p < 0.01 or ∗∗∗p < 0.001
were considered to be statistically significant.
RESULTS
Expression of Recombinant InsB Protein
and the Antigen-Specific IFN-γ
Response
The InsB gene was cloned and expressed as described previously
(Park et al., 2014). CD4+ Th1 cells and type-1 cytokines are
essential for resistance to Mtb infection; IFN-γ is a key CD4+ Th1
cell-derived cytokine and could serve as a marker of recognition
by the host immune system (Coler et al., 2018). Therefore, we
first investigated the production of antigen-specific IFN-γ prior
to challenge with an Mtb strain through ELISA (Figure 1A) and
flow cytometry (Figures 1B–D). For this experiment, mice were
immunized with InsB, and the control groups were immunized
with BCG, ESAT-6, or MPL-DDA, which was used as an adjuvant.
After final immunization, lung cells and splenocytes from all
groups were stimulated with InsB and ESAT-6, respectively.
When stimulated with antigens, lung and spleen cells of the
InsB-immunized groups showed significantly increased IFN-γ
production compared with those of the adjuvant control group
(MPL-DDA); interestingly, this production showed a similar
pattern (increased IFN-γ production) to those of the ESAT-6-
immunized groups (Figure 1A). In addition, populations of IFN-
γ-producing T cells (IFN-γ-producing CD4+ and CD8+) were
analyzed in the spleen and lung cells of the immunized groups. As
a consequence, increased frequencies of IFN-γ-producing CD4+
and CD8+ T cells were observed in the spleen (Figures 1B,C) and
the lung (Figure 1D) of InsB- and ESAT-6-immunized groups.
However, InsB- or ESAT-6-specific IFN-γ production was not
observed in the BCG vaccine groups, which was expected because
neither protein is included in the BCG vaccine (Figures 1A–D).
These results indicate that InsB has immunogenic potential and
that immunization with InsB induces a comparable Th1 immune
response to that induced by ESAT-6 immunization.
Multifunctional T Cells Induced in Mice
Immunized With InsB Prior to Mtb Strain
Challenge
Although immune correlates of protection against TB in humans
have not yet been determined, multifunctional Th1-type T
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FIGURE 1 | Immunogenicity in the lung and spleen of ESAT-6- and InsB-immunized mice. (A) At 3 weeks after the last immunization, mice (n = 6 mice/group) were
immunized with ESAT-6, InsB, adjuvant alone (MPL-DDA), or BCG, and their splenocytes and lung cells were stimulated in vitro with no antigen, with ESAT-6, or with
InsB for 24 h at 37◦C. IFN-γ secretion by spleen and lung cells in response to ESAT-6 and InsB stimulation was analyzed by ELISA. (B–D) Spleen and lung cells were
stimulated in vitro with no antigen, with ESAT-6, or with InsB in the presence of GolgiStop for 12 h at 37◦C. The representative plot for IFN-g-producing CD4+ and
CD8+ T cells in every vaccinated group of spleen is presented in (B). The percentages of IFN-γ-producing CD4+ and CD8+ T cells of spleen (C) and lung (D) were
analyzed by flow cytometry. The mean ± SDs (n = 6 mice/group) shown are representative of two independent experiments. Data from one of two independent
experiments are shown. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. n.s., no significant difference.
cells (that produce IFN-γ, TNF-α, and IL-2) are considered a
major component contributing to protection in animal models
(Flynn and Bloom, 1996; Flynn, 2004; Nandakumar et al.,
2014; Karp et al., 2015; Coler et al., 2018). Therefore, we next
investigated the frequency and proportion of antigen-specific
single- (IFN-γ+-, TNF-α+-, IL-2+-producing T cells), double-
(IFN-γ+TNF-α+-, IFN-γ+IL-2+-, TNF-α+IL-2+-producing T
cells) or triple-positive multifunctional T cells (IFN-γ+TNF-
α+IL-2+-producing T cells) after gating CD3+CD4+CD44+
and CD3+CD8+CD44+ cells by multicolor flow cytometric
analysis (Supplementary Figure S1). At 3 weeks after the final
immunization, lung cells and splenocytes of InsB-, ESAT-6- and
BCG-immunized mice were restimulated with InsB and ESAT-6,
respectively, and the MPL-DDA-injected group was used as the
control. InsB- and ESAT-6-immunized groups showed higher
levels of triple-positive and double-positive (IFN-γ+TNF-α+)
CD3+CD4+CD44+ T cells in lung cells (Figures 2A,C) and
splenocytes (Supplementary Figures S2A,C) than did the control
group injected with MPL-DDA; interestingly, these cell types
induced by InsB immunization were significantly increased to
a similar extent to that induced by ESAT-6 immunization. For
CD8+ T cells, triple-positive and double-positive (IFN-γ+TNF-
α+ and IFN-γ+TNF-α+) CD3+CD8+CD44+ T cells were
observed only in the spleens of InsB- and ESAT-6-immunized
mice (Supplementary Figures S2B,C), but significant differences
between InsB and ESAT-6 immunization were not reported.
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FIGURE 2 | Induction of antigen-specific multifunctional T cells in the lung of ESAT-6- and InsB-immunized mice. At 3 weeks after the last immunization, lung cells
from adjuvant (MPL-DDA)-, BCG-, ESAT-6-, or InsB-immunized mice (n = 6 mice/group) were stimulated in vitro with no antigen, with ESAT-6, or with InsB in the
presence of GolgiStop for 12 h at 37◦C. The percentage of antigen-specific CD3+CD4+CD44+ (A) and CD3+CD8+CD44+ (B) T cells producing IFN-γ, TNF-α, or
IL-2 was measured according to the gating strategy shown in Supplementary Figure 1. The frequency of T cells producing each combination of cytokines is
shown as the percentage of the specific cell type in the CD3+CD4+CD44+ or CD3+CD8+CD44+ T cell population. The mean ± SDs (n = 6 mice/group) shown are
representative of two independent experiments. ∗p < 0.05 (InsB vs. ESAT-6-immunized group) and #p < 0.05, ##p < 0.01, ###p < 0.001 (antigen-immunized groups
vs. each antigen-treated MPL-DDA group). To reduce false positives of cytokine-producing populations caused by non-specific staining, fewer than 10 cells in lung
and 15 cells in spleen were considered as zero. (C) Pie charts represent the mean frequencies of cells coexpressing IFN-γ, TNF-α, or IL-2.
These results indicated that InsB is a potential candidate antigen
for inducing an effective Th1 immune response.
Protective Efficacy of Antigen
Immunization Against Mtb K Infection
With Respect to Bacterial Growth and
Histopathology
Based on the immunological results of InsB immunization, we
next measured the protective efficacy of InsB immunization
against Mtb K challenge. Four weeks after the final
immunization, mice were infected with Mtb K via the
aerosol route. Four and nine weeks after Mtb K challenge,
bacterial load and histopathological analysis were examined
in the naive, MPL-DDA-injected control and in the BCG-
, ESAT-6- and InsB-immunized groups. Hematoxylin
and eosin (H&E) staining of lung tissues indicated that
InsB immunization induced a reduction in granulomatous
inflammation to a similar extent to that conferred by ESAT-
6 immunization at 4 and 9 weeks postchallenge of Mtb
K-infected mice. Moreover, this reduced lung inflammation
was comparable to that of the BCG-immunized group
at 9 weeks postchallenge (Figure 3A). In addition, InsB
immunization resulted in a decreased bacterial burden in
the lung and spleen, and this decrease was as great as that
in the ESAT-6 or BCG-immunized groups; furthermore,
these protective efficacies were sustained until 9 weeks
postinfection (Figure 3B). These results suggest that InsB
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FIGURE 3 | Protective efficacy of antigen immunization against Mtb K infection. (A) H&E-stained sections (n = 6 mice/group) of the lung from naive, adjuvant alone
(MPL-DDA)-, BCG-, ESAT-6-, or InsB-immunized mice at 4 and 9 weeks after challenge with the aerosolized Mtb K strain (20X: Scale bar = 100 µm). The
experimental results represent the relative percentages of inflamed area to unaffected area of lungs from uninfected mice as box-and-whisker plots. (B) Bacterial
numbers in the lung and spleen of adjuvant-, BCG-, InsB-, or ESAT-6-immunized mice at 4 and 9 weeks after Mtb K challenge are shown. The mean estimated log10
CFUs ± SDs (n = 6 mice/group) shown are representative of two independent experiments. One-way ANOVA followed by Tukey’s multiple comparison test was
used to evaluate the significance. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. n.s., no significant difference.
subunit vaccination may offer a protective efficacy similar to that
of BCG or ESAT-6.
Induced InsB-Specific Effective
Multifunctional T Cell Immunity After
Challenge With Mtb in the Spleen and
Lung
Depending on the outcome of the immunization, we next
evaluated whether the Th1 immune response generated by
immunization with InsB would continue producing effective
multifunctional T cells after challenge with virulent Mtb in
the spleen and lung over time. To this end, each immunized
group was challenged with Mtb after final immunization.
Four and 9 weeks after the Mtb challenge, spleen and
lung cells from mice were stimulated with InsB and ESAT-
6, respectively. The spleen and lung cells were stained
for a multifunctional T cell analysis, and the frequency
of bi- or triple-positive CD4+ and CD8+ T cells was
analyzed with flow cytometry. As a result, in the InsB-
and ESAT-6-immunized groups, triple- and double (IFN-
γ+TNF-α+IL-2+, IFN-γ+TNF-α+, IFN-γ+IL-2+, and TNF-
α+IL-2+)-positive CD3+CD44+CD4+ and CD3+CD44+CD8+
T cells were observed in both the lung (Figure 4) and
spleen (Supplementary Figure S3) compared to those in
the MPL-DDA-control groups (each antigen-stimulated MPL-
DDA group) at 4 weeks postchallenge. Although more potent
multifunctional T cell populations were observed in the
ESAT-6-immunized group, the InsB-immunized group showed
similar profiles of cytokines secreting CD4+ and CD8+ T
Frontiers in Microbiology | www.frontiersin.org 7 February 2019 | Volume 10 | Article 220
fmicb-10-00220 February 9, 2019 Time: 17:8 # 8
Kim et al. Evaluation of InsB Vaccine Potential
FIGURE 4 | Induction of antigen-specific multifunctional T cells in the lung of ESAT-6- and InsB-immunized mice at 4 weeks postinfection. Four weeks postinfection,
lung cells from adjuvant (MPL-DDA)-, BCG-, ESAT-6-, or InsB-immunized mice (n = 6 mice/group) were stimulated in vitro with no antigen, with ESAT-6, or with InsB
in the presence of GolgiStop for 12 h at 37◦C. The cell staining method for the multifunctional T cells is presented in the Materials and Methods section. The
percentage of antigen-specific CD3+CD4+CD44+ (A) and CD3+CD8+CD44+ (B) T cells producing IFN-γ, TNF-α, or IL-2 was analyzed using flow cytometry. The
frequency of T cells producing each combination of cytokines is presented as the percentage of the specific cell type in the CD3+CD4+CD44+ or
CD3+CD8+CD44+ T cell population. The mean ± SDs (n = 6 mice/group) shown are representative of two independent experiments. ∗p < 0.05 (InsB vs.
ESAT-6-immunized group) and #p < 0.05, ##p < 0.01, ###p < 0.001 (antigen-immunized groups vs. each antigen-treated MPL-DDA group). To reduce false
positives of cytokine-producing populations caused by non-specific staining, fewer than 10 cells in lung and 15 cells in spleen were considered as zero. (C) Pie
charts represent the mean frequencies of cells coexpressing IFN-γ, TNF-α, or IL-2.
cells (Figure 4 and Supplementary Figure S3). These aspects
were observed up to 9 weeks postinfection (Figure 5 and
Supplementary Figure S4). Taken together, the results show
that immunization with InsB can produce multifunctional
Th1 CD4+ T cells, including CD8+ T cells, and that these
reactions might remain for a long time after virulent Mtb
strain infection.
DISCUSSION
Various approaches have been proposed and explored for
potential use in TB control. Particularly, prophylactic vaccines
have the potential to be less costly and more efficacious
than BCG vaccines. Accumulating evidence for a protective
immunological response to Mtb infection has shown the
importance of the cellular immune response, especially involving
the generation of IFN-γ-producing antigen-specific CD4+ T
cells (Coler et al., 2009). A critical role of IFN-γ in the
control of Mtb infection has also been demonstrated in
both animals (Cooper et al., 1993; Flynn et al., 1993) and
humans (Jouanguy et al., 1996; Newport et al., 1996). Thus,
a general strategy to develop the next generation of TB
vaccines is to construct subunit vaccines based on T cell
antigens (Xiang et al., 2017). In the current study, our results
demonstrated that IFN-γ production (Figure 1) and Th1-
type multifunctional T cells (Figure 2 and Supplementary
Figure S2) were observed in lung and spleen cells from mice
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FIGURE 5 | Induction of antigen-specific multifunctional T cells in the lung of ESAT-6- and InsB-immunized mice at 9 weeks postinfection. Nine weeks postinfection,
lung cells from adjuvant (MPL-DDA)-, BCG-, ESAT-6-, or InsB-immunized mice (n = 6 mice/group) were stimulated in vitro with no antigen, with ESAT-6, or with InsB
in the presence of GolgiStop for 12 h at 37◦C. The percentage of antigen-specific CD3+CD4+CD44+ (A) and CD3+CD8+CD44+ (B) T cells producing IFN-γ,
TNF-α, or IL-2 was analyzed using flow cytometry. The frequency of T cells producing each combination of cytokines is presented as the percentage of the specific
cell type in the CD3+CD4+CD44+ or CD3+CD8+CD44+ T cell population. The mean ± SDs (n = 6 mice/group) shown are representative of two independent
experiments. ∗p < 0.05, ∗∗p < 0.01 (InsB vs. ESAT-6-immunized group) and #p < 0.05, ##p < 0.01, ###p < 0.001 (antigen-immunized groups vs. each
antigen-treated MPL-DDA group). To reduce false positives of cytokine-producing populations caused by non-specific staining, fewer than 10 cells in lung and 15
cells in spleen were considered as zero. (C) Pie charts represent the mean frequencies of cells coexpressing IFN-γ, TNF-α, or IL-2.
immunized with InsB to a similar extent to that observed
after immunization with ESAT-6, indicating that InsB elicited
an antigen-specific Th1 polarized immune response as an
immunogenic antigen.
The identification of Mtb antigens eliciting antigen-specific
IFN-γ–producing CD4+ T cell responses during Mtb infection
has been approached through a variety of methods, including
comparative proteomics using biochemical fractionation of
the Mtb-secreted antigen pool, comparative transcriptomic
analysis, and in silico epitope analysis (Shah et al., 2018).
The identification of ESAT-6/Rv3875 (Sorensen et al., 1995)
and Mtb10.4/Rv0288 (Skjot et al., 2000) via comparative
proteomic analysis in a culture filtrate from Mtb is a successful
example. Another successful example is the identification of
Mtb9.8/Rv0287 using a human CD4+ T cell expression cloning
approach (Alderson et al., 2000; Coler et al., 2009). These single
antigens were integrated into multiantigenic subunit vaccines
and are currently entered into the clinical pipeline for new TB
vaccine development (Andersen and Kaufmann, 2014). Although
these applications have been attempted in many studies, it
may be labor-intensive to identify and characterize a single
antigen. In the present study, we first identified InsB to be
uniquely present in the genome of Mtb K, which is the
most prevalent clinical isolate in Korea, by taking advantage
of a recent advance in comparative genomic analysis. In
particular, InsB has been proven to stimulate the immune
Frontiers in Microbiology | www.frontiersin.org 9 February 2019 | Volume 10 | Article 220
fmicb-10-00220 February 9, 2019 Time: 17:8 # 10
Kim et al. Evaluation of InsB Vaccine Potential
response and to have an additive effect to that of ESAT-6 (Park
et al., 2014). In addition, InsB showed a comparable antigen-
specific Th1-type T-cell response to that induced by ESAT-6,
and its immunization demonstrated a remarkable protection
efficacy against Mtb K challenge to a similar extent to that
with ESAT-6.
In fact, based on its immunodiagnostic potency and protective
effectiveness, ESAT-6 is considered the strongest vaccine
candidate. ESAT-6 is located in RD1 of the Mtb genome,
which is absent in M. bovis BCG, and potent T cell antigens
with low molecular weights were first identified from a short-
term culture filtrate of Mtb (Andersen et al., 1995). Along
with the effectors of ESX-1, the antigens encoded in ESX-
3 and ESX-5 are also potent inducers of CD4+ and CD8+
T cells (Brodin et al., 2006; Hoang et al., 2013). These
investigations prompted immunological studies of other Esx
proteins to determine whether they could display immunogenic
qualities (Brodin et al., 2004). These other ESAT-6 family
proteins have also received much attention recently with
respect to understanding Mtb pathogenesis and characterizing
their role in TB vaccine development (Skjot et al., 2002;
Homolka et al., 2010). Thus, we identified the Mtb K-specific
ESAT-6-like protein InsB and evaluated its protective efficacy
against Mtb.
Jones et al. (2010) recently demonstrated similar levels of
immunogenicity of the other Esx proteins produced outside
the ESX-1 to ESX-5 loci to those of Esx proteins from the
ESX-1 to ESX-5 loci. Interestingly, a comparative analysis of
Esx genes from clinical isolates of Mtb revealed evidence of
gene conversion and epitope variation (Uplekar et al., 2011),
particularly among the Mtb9.9 subfamily proteins. Strikingly,
even single-amino acid residue differences in the epitope
sequences among Mtb9.9 subfamily proteins, which share a
high degree of amino acid sequence similarity (93–98%), altered
the responder frequencies to individual antigens. In addition,
heterogeneous human T cell responses to the Mtb9.9 subfamily
proteins were reported (Alderson et al., 2000; Hur et al., 2016).
In the present study, we confirmed that there was no cross-
reactivity between ESAT-6 and InsB in the induction of cellular
and humoral immune responses after each protein immunization
(data not shown), which agrees with the results from our previous
study (Park et al., 2014).
We finally evaluated the protective efficacy of InsB
in a preclinical animal model setting against Mtb K.
Interestingly, InsB immunization displayed a similar long-
term protective efficacy (up to 9 weeks postinfection) to
that of ESAT-6 immunization after challenge with Mtb K
based on assessments of lung pathology (Figure 3A) and
the reduced bacterial burden (Figure 3B). Although the
definitive protective correlates have not been fully elucidated,
particularly in humans, the multifunctional abilities of Th1-
type T cells were recently shown to be associated with
protection against Mtb infection in mouse models (Flynn
and Bloom, 1996; Flynn, 2004; Forbes et al., 2008; Karp
et al., 2015; Coler et al., 2018). In addition, a continuous
decrease in the multifunctionality of T cells corresponds
with a decrease in protection during Mtb infection in a
mouse model (Nandakumar et al., 2014). We thus detected
the maintenance of CD4+ T cells capable of producing
double- or triple-positive (coexpressing IFN-γ, TNF, and
IL-2) Th1 cells via immunization with InsB to a similar
extent to that of the multifunctionalities induced by ESAT-
6 immunization (Figures 2, 4, 5), suggesting that InsB
can be used as a potential vaccine candidate exhibiting
immune-stimulatory properties.
In summary, as demonstrated in a murine model, InsB
immunization induces strong immunogenicity and has
the ability to induce a robust and durable antigen-specific
multifunctional Th1-type T cell memory response that
confers protective immunity and significant protection
against Mtb K, similarly to the effects induced by ESAT-
6. These results indicate that InsB is a potential antigen
target for the development of future multiantigenic vaccines
against Mtb, especially against highly virulent Mtb Beijing
strains. However, the evaluation of vaccine efficacy against
laboratory-adapted Mtb strains cannot fully reflect the
clinical situation (McShane and Williams, 2014; Henao-
Tamayo et al., 2015). The Mtb Beijing family, including
the K strain, shows a notably higher prevalence and is
more frequently isolated in comparison to other Mtb
strains (Kang et al., 2010). Therefore, to develop broad-
spectrum subunit vaccines against TB, InsB should be
further evaluated against non-Beijing Mtb strains as well.
In addition, further evaluation of InsB as a booster of the
BCG vaccine or in combination with other Esx proteins
such as ESAT-6 or TB10.4 to boost additional protective
immunity will guarantee the usefulness of InsB as a
vaccine antigen.
AUTHOR CONTRIBUTIONS
WK, HK, and KK performed the experiments and analyzed
the data. S-NC provided tools and critical assistance with
experimental procedures. SS and WK designed the experiments,
interpreted the data, and wrote the manuscript.
FUNDING
This research was supported by a grant from Basic
Science Research Program (NRF-2016R1A2A1A05005263)
and by the Korea Mouse Phenotyping Project (NRF-
2017M3A9D5A01052446) through the National Research
Foundation of Korea (NRF) funded by the Ministry of science,
ICT and Future Planning.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fmicb.2019.
00220/full#supplementary-material
Frontiers in Microbiology | www.frontiersin.org 10 February 2019 | Volume 10 | Article 220
fmicb-10-00220 February 9, 2019 Time: 17:8 # 11
Kim et al. Evaluation of InsB Vaccine Potential
REFERENCES
Abebe, F., and Bjune, G. (2006). The emergence of Beijing family genotypes
of Mycobacterium tuberculosis and low-level protection by bacille Calmette-
Guerin (BCG) vaccines: is there a link? Clin. Exp. Immunol. 145, 389–397.
doi: 10.1111/j.1365-2249.2006.03162.x
Alderson, M. R., Bement, T., Day, C. H., Zhu, L., Molesh, D., Skeiky, Y. A., et al.
(2000). Expression cloning of an immunodominant family of Mycobacterium
tuberculosis antigens using human CD4(+) T cells. J. Exp. Med. 191, 551–560.
doi: 10.1084/jem.191.3.551
Andersen, P., Andersen, A. B., Sorensen, A. L., and Nagai, S. (1995). Recall of long-
lived immunity to Mycobacterium tuberculosis infection in mice. J. Immunol.
154, 3359–3372.
Andersen, P., and Kaufmann, S. H. (2014). Novel vaccination strategies against
tuberculosis. Cold Spring Harb. Perspect. Med. 4:a018523. doi: 10.1101/
cshperspect.a018523
Brodin, P., Majlessi, L., Brosch, R., Smith, D., Bancroft, G., Clark, S., et al. (2004).
Enhanced protection against tuberculosis by vaccination with recombinant
Mycobacterium microti vaccine that induces T cell immunity against region
of difference 1 antigens. J. Infect. Dis. 190, 115–122. doi: 10.1086/4
21468
Brodin, P., Majlessi, L., Marsollier, L., de Jonge, M. I., Bottai, D., Demangel, C.,
et al. (2006). Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis
and impact on immunogenicity and virulence. Infect. Immun. 74, 88–98. doi:
10.1128/iai.74.1.88-98.2006
Chae, H., and Shin, S. J. (2018). Importance of differential identification of
Mycobacterium tuberculosis strains for understanding differences in their
prevalence, treatment efficacy, and vaccine development. J. Microbiol. 56,
300–311. doi: 10.1007/s12275-018-8041-3
Chiner-Oms, A., Gonzalez-Candelas, F., and Comas, I. (2018). Gene expression
models based on a reference laboratory strain are poor predictors of
Mycobacterium tuberculosis complex transcriptional diversity. Sci. Rep. 8:3813.
doi: 10.1038/s41598-018-22237-5
Choi, H. G., Choi, S., Back, Y. W., Paik, S., Park, H. S., Kim, W. S., et al.
(2017). Rv2299c, a novel dendritic cell-activating antigen of Mycobacterium
tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable
protection against the hypervirulent strain HN878 in mice. Oncotarget 8,
19947–19967. doi: 10.18632/oncotarget.15256
Choi, H. G., Kim, W. S., Back, Y. W., Kim, H., Kwon, K. W., Kim, J. S., et al. (2015).
Mycobacterium tuberculosis RpfE promotes simultaneous Th1- and Th17-type
T-cell immunity via TLR4-dependent maturation of dendritic cells. Eur. J.
Immunol. 45, 1957–1971. doi: 10.1002/eji.201445329
Coler, R. N., Day, T. A., Ellis, R., Piazza, F. M., Beckmann, A. M., Vergara, J., et al.
(2018). The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality
of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human
trial. NPJ Vaccines 3:34. doi: 10.1038/s41541-018-0057-5
Coler, R. N., Dillon, D. C., Skeiky, Y. A., Kahn, M., Orme, I. M., Lobet, Y., et al.
(2009). Identification of Mycobacterium tuberculosis vaccine candidates using
human CD4+ T-cells expression cloning. Vaccine 27, 223–233. doi: 10.1016/j.
vaccine.2008.10.056
Cooper, A. M., Dalton, D. K., Stewart, T. A., Griffin, J. P., Russell, D. G., and Orme,
I. M. (1993). Disseminated tuberculosis in interferon gamma gene-disrupted
mice. J. Exp. Med. 178, 2243–2247. doi: 10.1084/jem.178.6.2243
Ernst, J. D. (2017). Antigenic variation and immune escape in the MTBC. Adv. Exp.
Med. Biol. 1019, 171–190. doi: 10.1007/978-3-319-64371-7_9
Flynn, J. L. (2004). Immunology of tuberculosis and implications in vaccine
development. Tuberculosis 84, 93–101. doi: 10.1016/j.tube.2003.08.010
Flynn, J. L., and Bloom, B. R. (1996). Role of T1 and T2 cytokines in the response to
Mycobacterium tuberculosis. Ann. N. Y. Acad. Sci. 795, 137–146. doi: 10.1111/j.
1749-6632.1996.tb52662.x
Flynn, J. L., Chan, J., Triebold, K. J., Dalton, D. K., Stewart, T. A., and Bloom, B. R.
(1993). An essential role for interferon gamma in resistance to Mycobacterium
tuberculosis infection. J. Exp. Med. 178, 2249–2254. doi: 10.1084/jem.178.6.2249
Forbes, E. K., Sander, C., Ronan, E. O., McShane, H., Hill, A. V., Beverley,
P. C., et al. (2008). Multifunctional, high-level cytokine-producing Th1 cells
in the lung, but not spleen, correlate with protection against Mycobacterium
tuberculosis aerosol challenge in mice. J. Immunol. 181, 4955–4964. doi: 10.
4049/jimmunol.181.7.4955
Groschel, M. I., Sayes, F., Shin, S. J., Frigui, W., Pawlik, A., Orgeur, M., et al. (2017).
Recombinant BCG expressing ESX-1 of Mycobacterium marinum combines
low virulence with cytosolic immune signaling and improved TB protection.
Cell Rep. 18, 2752–2765. doi: 10.1016/j.celrep.2017.02.057
Groschel, M. I., Sayes, F., Simeone, R., Majlessi, L., and Brosch, R. (2016). ESX
secretion systems: mycobacterial evolution to counter host immunity. Nat. Rev.
Microbiol. 14, 677–691. doi: 10.1038/nrmicro.2016.131
Han, S. J., Song, T., Cho, Y. J., Kim, J. S., Choi, S. Y., Bang, H. E., et al. (2015).
Complete genome sequence of Mycobacterium tuberculosis K from a Korean
high school outbreak, belonging to the Beijing family. Stand. Genomic Sci. 10:78.
doi: 10.1186/s40793-015-0071-4
Henao-Tamayo, M., Shanley, C. A., Verma, D., Zilavy, A., Stapleton, M. C., Furney,
S. K., et al. (2015). The efficacy of the BCG vaccine against newly emerging
clinical strains of Mycobacterium tuberculosis. PloS One 10:e0136500. doi: 10.
1371/journal.pone.0136500
Hoang, T., Aagaard, C., Dietrich, J., Cassidy, J. P., Dolganov, G., Schoolnik,
G. K., et al. (2013). ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre-
and post-exposure tuberculosis vaccination. PloS One 8:e80579. doi: 10.1371/
journal.pone.0080579
Homolka, S., Niemann, S., Russell, D. G., and Rohde, K. H. (2010). Functional
genetic diversity among Mycobacterium tuberculosis complex clinical isolates:
delineation of conserved core and lineage-specific transcriptomes during
intracellular survival. PLoS Pathog. 6:e1000988. doi: 10.1371/journal.ppat.
1000988
Hur, Y. G., Chung, W. Y., Kim, A., Kim, Y. S., Kim, H. S., Jang, S. H., et al. (2016).
Host immune responses to antigens derived from a predominant strain of
Mycobacterium tuberculosis. J. Infect. 73, 54–62. doi: 10.1016/j.jinf.2016.04.032
Jeon, B. Y., Kim, S. C., Eum, S. Y., and Cho, S. N. (2011). The immunity and
protective effects of antigen 85A and heat-shock protein X against progressive
tuberculosis. Microb. Infect. 13, 284–290. doi: 10.1016/j.micinf.2010.11.002
Jones, G. J., Gordon, S. V., Hewinson, R. G., and Vordermeier, H. M. (2010).
Screening of predicted secreted antigens from Mycobacterium bovis reveals
the immunodominance of the ESAT-6 protein family. Infect. Immun. 78,
1326–1332. doi: 10.1128/iai.01246-09
Jouanguy, E., Altare, F., Lamhamedi, S., Revy, P., Emile, J. F., Newport, M., et al.
(1996). Interferon-gamma-receptor deficiency in an infant with fatal bacille
Calmette-Guerin infection. N. Engl. J. Med. 335, 1956–1961. doi: 10.1056/
nejm199612263352604
Kang, H. Y., Wada, T., Iwamoto, T., Maeda, S., Murase, Y., Kato, S., et al. (2010).
Phylogeographical particularity of the Mycobacterium tuberculosis Beijing
family in South Korea based on international comparison with surrounding
countries. J. Med. Microbiol. 59, 1191–1197. doi: 10.1099/jmm.0.022103-0
Karp, C. L., Wilson, C. B., and Stuart, L. M. (2015). Tuberculosis vaccines: barriers
and prospects on the quest for a transformative tool. Immunol. Rev. 264,
363–381. doi: 10.1111/imr.12270
Kaufmann, S. H. E., Dockrell, H. M., Drager, N., Ho, M. M., McShane, H.,
Neyrolles, O., et al. (2017). TBVAC2020: advancing tuberculosis vaccines from
discovery to clinical development. Front. Immunol. 8:1203. doi: 10.3389/fimmu.
2017.01203
Kim, J. S., Kim, W. S., Choi, H. G., Jang, B., Lee, K., Park, J. H., et al. (2013).
Mycobacterium tuberculosis RpfB drives Th1-type T cell immunity via a TLR4-
dependent activation of dendritic cells. J. Leukoc. Biol. 94, 733–749. doi: 10.
1189/jlb.0912435
Kim, W. S., Kim, J. S., Cha, S. B., Han, S. J., Kim, H., Kwon, K. W., et al.
(2015). Virulence-dependent alterations in the kinetics of immune cells during
pulmonary infection by Mycobacterium tuberculosis. PloS One 10:e0145234.
doi: 10.1371/journal.pone.0145234
Knudsen, N. P., Norskov-Lauritsen, S., Dolganov, G. M., Schoolnik, G. K.,
Lindenstrom, T., Andersen, P., et al. (2014). Tuberculosis vaccine with high
predicted population coverage and compatibility with modern diagnostics.
Proc. Natl. Acad. Sci. U.S.A. 111, 1096–1101. doi: 10.1073/pnas.13149
73111
Kremer, K., van-der-Werf, M. J., Au, B. K., Anh, D. D., Kam, K. M., van-
Doorn, H. R., et al. (2009). Vaccine-induced immunity circumvented by typical
Mycobacterium tuberculosis Beijing strains. Emerg. Infect. Dis. 15, 335–339.
doi: 10.3201/eid1502.080795
Kwon, K. W., Kim, W. S., Kim, H., Han, S. J., Hahn, M. Y., Lee, J. S., et al.
(2017). Novel vaccine potential of Rv3131, a DosR regulon-encoded putative
Frontiers in Microbiology | www.frontiersin.org 11 February 2019 | Volume 10 | Article 220
fmicb-10-00220 February 9, 2019 Time: 17:8 # 12
Kim et al. Evaluation of InsB Vaccine Potential
nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K. Sci.
Rep. 7:44151. doi: 10.1038/srep44151
Mahmood, A., Srivastava, S., Tripathi, S., Ansari, M. A., Owais, M., and Arora, A.
(2011). Molecular characterization of secretory proteins Rv3619c and Rv3620c
from Mycobacterium tuberculosis H37Rv. FEBS J. 278, 341–353. doi: 10.1111/j.
1742-4658.2010.07958.x
McShane, H., and Williams, A. (2014). A review of preclinical animal
models utilised for TB vaccine evaluation in the context of recent
human efficacy data. Tuberculosis 94, 105–110. doi: 10.1016/j.tube.2013.
11.003
Nandakumar, S., Kannanganat, S., Posey, J. E., Amara, R. R., and Sable,
S. B. (2014). Attrition of T-cell functions and simultaneous upregulation of
inhibitory markers correspond with the waning of BCG-induced protection
against tuberculosis in mice. PloS One 9:e113951. doi: 10.1371/journal.pone.01
13951
Nemes, E., Geldenhuys, H., Rozot, V., Rutkowski, K. T., Ratangee, F., Bilek, N.,
et al. (2018). Prevention of M. tuberculosis infection with H4:IC31 vaccine or
BCG revaccination. N. Engl. J. Med. 379, 138–149. doi: 10.1056/NEJMoa171
4021
Newport, M. J., Huxley, C. M., Huston, S., Hawrylowicz, C. M., Oostra, B. A.,
Williamson, R., et al. (1996). A mutation in the interferon-gamma-receptor
gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335,
1941–1949. doi: 10.1056/nejm199612263352602
Park, P. J., Kim, A. R., Salch, Y. P., Song, T., Shin, S. J., Han, S. J., et al. (2014).
Characterization of a novel antigen of Mycobacterium tuberculosis K strain
and its use in immunodiagnosis of tuberculosis. J. Microbiol. 52, 871–878.
doi: 10.1007/s12275-014-4235-5
Peng, C., Zhang, L., Liu, D., Xu, W., Hao, K., Cui, Z., et al. (2012). Mtb9.9 protein
family: an immunodominant antigen family of Mycobacterium tuberculosis
induces humoral and cellular immune responses in mice. Hum. Vaccines
Immunother. 8, 435–442. doi: 10.4161/hv.18861
Pitt, J. M., Blankley, S., McShane, H., and O’Garra, A. (2013). Vaccination against
tuberculosis: how can we better BCG? Microb. Pathog. 58, 2–16. doi: 10.1016/j.
micpath.2012.12.002
Shah, P., Mistry, J., Reche, P. A., Gatherer, D., and Flower, D. R. (2018).
In silico design of Mycobacterium tuberculosis epitope ensemble vaccines. Mol.
Immunol. 97, 56–62. doi: 10.1016/j.molimm.2018.03.007
Singh, S., Saraav, I., and Sharma, S. (2014). Immunogenic potential of latency
associated antigens against Mycobacterium tuberculosis. Vaccine 32, 712–716.
doi: 10.1016/j.vaccine.2013.11.065
Skjot, R. L., Brock, I., Arend, S. M., Munk, M. E., Theisen, M., Ottenhoff, T. H., et al.
(2002). Epitope mapping of the immunodominant antigen TB10.4 and the two
homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the
esat-6 gene family. Infect. Immun. 70, 5446–5453. doi: 10.1128/IAI.70.10.5446-
5453.2002
Skjot, R. L., Oettinger, T., Rosenkrands, I., Ravn, P., Brock, I., Jacobsen, S.,
et al. (2000). Comparative evaluation of low-molecular-mass proteins from
Mycobacterium tuberculosis identifies members of the ESAT-6 family as
immunodominant T-cell antigens. Infect. Immun. 68, 214–220. doi: 10.1128/
IAI.68.1.214-220.2000
Sorensen, A. L., Nagai, S., Houen, G., Andersen, P., and Andersen, A. B. (1995).
Purification and characterization of a low-molecular-mass T-cell antigen
secreted by Mycobacterium tuberculosis. Infect. Immun. 63, 1710–1717.
Uplekar, S., Heym, B., Friocourt, V., Rougemont, J., and Cole, S. T. (2011).
Comparative genomics of Esx genes from clinical isolates of Mycobacterium
tuberculosis provides evidence for gene conversion and epitope variation. Infect.
Immun. 79, 4042–4049. doi: 10.1128/iai.05344-11
Valway, S. E., Sanchez, M. P., Shinnick, T. F., Orme, I., Agerton, T., Hoy, D.,
et al. (1998). An outbreak involving extensive transmission of a virulent strain
of Mycobacterium tuberculosis. N. Engl. J. Med. 338, 633–639. doi: 10.1056/
nejm199803053381001
van Soolingen, D., Qian, L., de Haas, P. E., Douglas, J. T., Traore, H., Portaels, F.,
et al. (1995). Predominance of a single genotype of Mycobacterium tuberculosis
in countries of east Asia. J. Clin. Microbiol. 33, 3234–3238.
Villarreal, D. O., Walters, J., Laddy, D. J., Yan, J., and Weiner, D. B. (2014).
Multivalent TB vaccines targeting the esx gene family generate potent and broad
cell-mediated immune responses superior to BCG. Hum. Vaccines Immunother.
10, 2188–2198. doi: 10.4161/hv.29574
WHO (2017). Global Tuberculosis Report 2017. Geneva: World Health
Organization.
Xiang, Z. H., Sun, R. F., Lin, C., Chen, F. Z., Mai, J. T., Liu, Y. X., et al.
(2017). Immunogenicity and protective efficacy of a fusion protein tuberculosis
vaccine combining five esx family proteins. Front. Cell. Infect. Microbiol. 7:226.
doi: 10.3389/fcimb.2017.00226
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Kim, Kim, Kwon, Cho and Shin. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Microbiology | www.frontiersin.org 12 February 2019 | Volume 10 | Article 220
